Shots:
- Gan & Lee Pharmaceuticals has initiated a P-III (GRADUAL-3) study of bofanglutide (GZR18) in adults with obesity or overweight
- The trial will assess the safety & efficacy of bofanglutide (SC, Q4W) in obese or overweight pts for 24wks., while evaluating the change and the percentage change from baseline in body weight at 24wk. as the 1EP
- Bofanglutide is being evaluated in the P-III (GRADUAL-1) trial in ~630 Chinese adults with obesity or overweight who have not achieved adequate weight loss through diet & exercise, & in the P-III (GRADUAL-2) trial against Wegovy in ~471 similar pts, with or without type 2 diabetes
Ref: PR Newswire | Image: Gan & Lee | Press Release
Related News:- Pfizer Expands into Obesity Treatments with ~$7.3B Metsera Acquisition
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
